Use of the Selective Serotonin 3 Receptor Antagonist Ondansetron in the Treatment of Neuroleptic-Induced Tardive Dyskinesia
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The authors examined the efficacy, tolerability, and safety of ondansetron, a selective serotonin 3 receptor antagonist, in patients with tardive dyskinesia. METHOD: Twenty patients with schizophrenia who had neuroleptic-induced tardive dyskinesia were given 12 mg/day of ondansetron for 12 weeks in an open-label study. RESULTS: Administration of ondansetron resulted in a statistically significant improvement in tardive dyskinesia and psychotic symptoms. CONCLUSIONS: Ondansetron may be an effective and safe therapy to control tardive dyskinesia and psychosis in patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Serotonin modulation of cortical neurons and networks
Celada, P., Puig, M. V., & Artigas, F. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00025 · Cited by 462
“These agents have been also reported to display anxiolytic and antipsychotic activity in animal models (Higgins and Kilpatrick, 1999) and to improve the therapeutic action of antipsychotic drugs in schizophrenic patients (Sirota et al., 2000).”
BackgroundOndansetron: A Selective 5‐HT3Receptor Antagonist and Its Applications in CNS‐Related Disorders
Ye, J., Ponnudurai, R., & Schaefer, R. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00195.x · Cited by 162
Bhatt, S., Devadoss, T., Manjula, S. N., & Rajangam, J. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666201015155816 · Cited by 119
Corrêa Filho, J. M., & Baltieri, D. A. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.12.018 · Cited by 26
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14f09704 · Cited by 14
Metadata
- Authors
- Sirota, P., Mosheva, T., Shabtay, H., Giladi, N., & Korczyn, A. D.
- Venue
- American Journal of Psychiatry
- Published
- 2000-02-01
- Volume
- 157
- Issue
- 2
- Pages
- 287-289
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2024744942
- Cited by
- 81
- References
- 0
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.